THIS WEBSITE IS FOR
HEALTHCARE PROFESSIONALS

 

This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) who are interested in information on ROZLYTREK®. If you are a US healthcare professional click here. The product has received EMA approval. The registration status and approved product labels of ROZLYTREK® may not be the same in the different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details. 

Request medical information

Prescribing information

Contact us

  • What is ROZLYTREK?
     
  • Introduction to ROZLYTREK
  • MoA and CNS activity
  • ROS1+ NSCLC
     
  • Study design
  • Patient characteristics
  • Efficacy
  • CNS efficacy
  • NTRK fusion+ solid tumours
     
  • Study design
  • Patient characteristics
  • Efficacy
  • CNS efficacy
  • ROZLYTREK safety overview
     
  • ROZLYTREK safety summary
  • ROZLYTREK adverse reactions
  • Monitoring
  • Prescribing ROZLYTREK
     
  • ROZLYTREK dosing
  • Download the ROZLYTREK SmPC
  • Patient benefits
     
  • Lung cancer patient
  • Breast cancer patient
  • Sarcoma patient
  • Gene fusion detection
     
  • Introduction to clinically actionable fusions
  • NTRK
  • ROS1
  • Testing guidelines
  • Disease support
     
  • Coming soon
Request medical information

Prescribing information

Contact us

Bring the potential of ROZLYTREK® to life

Disease support

Disease support

Coming soon

© 2021. RF. Hoffmann-La Roche Ltd.

About Roche

Contact Us
Legal statement
Privacy

Cookie Preferences

Your local partner

M-XX-00003955 Date of preparation: July 2021

This site is intended for those outside the United States.